-
公开(公告)号：WO2009104907A2
公开(公告)日：2009-08-27
申请号：PCT/KR2009/000783
申请日：2009-02-18
IPC: C12N5/08
CPC classification number: C12N5/0695 , C12N2501/11 , C12N2501/115 , C12N2501/235
Abstract: 본 발명은 유방암 조직으로부터 유래되고 유방암 줄기세포 표지 인자를 발현하는 다능성 암 줄기 세포주 및 (1) 기 채취된 유방암 조직으로부터 유방암 세포를 분리하는 단계; (2) 상기 분리된 유방암 세포를 부유 배양용 배지에서 부유 상태로 일차 배양하는 단계; (3) 상기 일차 배양물로부터 부유 상태의 세포들을 회수하는 단계; 및 (4) 회수된 세포들을 부유 배양용 배지에서 부유 상태로 일정 회수 이상 계대 배양하여 다능성 암 줄기 세포주를 제조하는 단계를 포함한 다능성 암 줄기 세포주의 제조방법에 관한 것이다.
Abstract translation:
本发明包括分离的多能干细胞的乳腺癌细胞的步骤，和（1）从乳腺癌组织衍生的基团所收集，并表示从乳腺癌组织乳腺癌干细胞标记物; （2）在悬浮培养基中以漂浮状态初次培养分离的乳腺癌细胞; （3）从原代培养物中回收悬浮细胞; （4）将回收的细胞在悬浮培养基中悬浮培养预定次数或更多次以产生多能癌症干细胞系。
-
公开(公告)号：KR1020090058726A
公开(公告)日：2009-06-10
申请号：KR1020070125455
申请日：2007-12-05
Applicant: 재단법인서울대학교산학협력재단
IPC: G01N33/574 , G01N33/68 , G01N33/53 , G01N33/48
Abstract: An autoantibody marker to alpha2-HS glycoprotein for diagnosing breast cancer and diagnosis kit are provided to confirm the amount of protein expression of autoantibody marker and early diagnose breast cancer. A diagnosis kit of breast cancer comprises alpha2-HS glycoprotein antigen which is specific to an autoantibody marker. The antigen is isolated from the urine of breast cancer patient. The antigen is isolated and purified from human blood. The diagnosis kit further comprises a marker of secondary antibody zygote, chromogenic substate rinse solution and enzyme reaction stopping solution. The marker of secondary antibody zygote is selected from HRP(horseradish peroxidase), alkaline phosphatase, coloid gold, fluorescein, and dye.
Abstract translation: 提供用于诊断乳腺癌的α2-HS糖蛋白的自身抗体标记和诊断试剂盒，以确认自身抗体标记物的蛋白质表达量和早期诊断乳腺癌。 乳腺癌的诊断试剂盒包括对自身抗体标记物特异的α2-HS糖蛋白抗原。 从乳腺癌患者的尿液中分离抗原。 从人血液中分离和纯化抗原。 诊断试剂盒还包含二次受体合子的标记物，显色基础漂洗溶液和酶反应停止溶液。 二次受体合子的标记选自HRP（辣根过氧化物酶），碱性磷酸酶，共轭金，荧光素和染料。
-
公开(公告)号：KR100868316B1
公开(公告)日：2008-11-11
申请号：KR1020050032872
申请日：2005-04-20
Applicant: 재단법인서울대학교산학협력재단
Abstract: 본 발명은 유방 조직에서 유래된 다능성 줄기 세포 및 (a) 유방 조직으로부터 유방 세포를 분리하는 단계; (b) 상기 유방 세포를 줄기 세포 배양용 배지에서 일차 배양하는 단계; (c) 상기 일차 배양물로부터 부유 상태의 세포들을 수집하는 단계; 및 (d) 상기 부유 상태의 세포들을 줄기 세포 배양용 배지에서 계대 배양하여 다능성 줄기 세포를 분리하는 단계를 포함한 유방 조직 유래의 다능성 줄기 세포의 제조방법에 관한 것이다.
또한, 본 발명은 상기 유방 조직 유래의 다능성 줄기 세포로부터 분화된 세포 및 (a) 유방 조직 유래의 다능성 줄기 세포를 목적 분화 세포 배양용 배지에서 배양하는 단계 및 (b) 배양 중에 목적 분화 세포의 마커를 발현하는 분화 세포를 분리하는 단계를 포함한 유방 조직 유래의 다능성 줄기 세포의 제조방법에 관한 것이다. 본 발명에 따른 유방 조직 유래의 다능성 줄기 세포는 상피 세포, 신경 세포 또는 골수 세포를 비롯하여 인체를 구성하는 여러 유형의 세포로 분화할 수 있다.-
公开(公告)号：KR1020080018619A
公开(公告)日：2008-02-28
申请号：KR1020060081022
申请日：2006-08-25
Applicant: 재단법인서울대학교산학협력재단
Abstract: A multipotential cell line II derived from cancer tissue is provided to differentiate into other cells such as epidermal cell and nerve cell except cells in the cancer tissue, and separate cancer stem cell, so that it is useful for treatment of various diseases. A method for preparing the multipotential cell line II(KCLRF-BP-00138) comprises the steps of: (1) separating cancer cells from the previously separated cancer tissue; (2) culturing the separated cancer cells in a suspension medium; (3) collecting the cells in a suspension state from the cultured medium; (4) subculturing the collected cells in a suspension medium to separate the multipotential cell line; and (5) optionally culturing the separated multipotential cell line in medium for adhesion. A multipotential cell line II(KCLRF-BP-00138) derived from cancer tissue and being cultured in a suspension state does not express markers of breast cancer diagnosis receptor(ER, PR, C-erBb2), and express markers of breast stem cell(CK19, CK5, CK6), a marker of breast cancer resistant drug(ABCG2), markers of epidermal cell(CK14, vimentin, CK18) and markers of nerve cell(nestin, Tuj-1). Further, the cancer tissue is breast cancer.
Abstract translation: 提供衍生自癌组织的多能细胞系II，以分化成其他细胞，如癌组织中除细胞外的表皮细胞和神经细胞，以及分离的癌干细胞，因此可用于治疗各种疾病。 制备多潜能细胞系II（KCLRF-BP-00138）的方法包括以下步骤：（1）从先前分离的癌组织分离癌细胞; （2）在悬浮介质中培养分离的癌细胞; （3）从培养基中收集处于悬浮状态的细胞; （4）将收集的细胞在悬浮培养基中传代培养以分离多潜能细胞系; 和（5）任选地在培养基中培养分离的多能细胞系以进行粘附。 衍生自癌组织并以悬浮状态培养的多能细胞系II（KCLRF-BP-00138）不表达乳腺癌诊断受体（ER，PR，C-erBb2）的标志物，并且表达乳腺干细胞的标志物 CK19，CK5，CK6），乳腺癌抗药物标记物（ABCG2），表皮细胞标志物（CK14，波形蛋白，CK18）和神经细胞标记物（nestin，Tuj-1）。 此外，癌组织是乳腺癌。
-
公开(公告)号：KR100991289B1
公开(公告)日：2010-11-01
申请号：KR1020070125455
申请日：2007-12-05
Applicant: 재단법인서울대학교산학협력재단
IPC: G01N33/574 , G01N33/68 , G01N33/53 , G01N33/48
Abstract: 본 발명은 유방암 진단용 자가항체마커 및 이를 이용한 진단키트에 관한 것이다. 보다 구체적으로 본 발명은 α2-HS 당단백질에 대한 자가항체마커 및 이의 항원인 α2-HS 당단백질을 포함하는 진단키트를 이용해 정상인과 유방암환자에서 자가항체마커 단백질 발현량 차이를 확인함으로써 유방암 조기진단에 유용하게 사용될 수 있다.
유방암, 진단용 마커, α2-HS 당단백질, 자가항체-
Patent Agency Ranking
公开(公告)号：KR1020090089120A
公开(公告)日：2009-08-21
申请号：KR1020080014498
申请日：2008-02-18
Applicant: 재단법인서울대학교산학협력재단
CPC classification number: C12N5/0695 , C12N2501/11 , C12N2501/115 , C12N2501/235
Abstract: A method for manufacturing multipotential cancer stem cell line is provided to overcome anticancer drug resistance and maximize the efficiency of treating cancer. A multipotential cancer cell line is derived from breast cancer tissue and expresses a marker of breast cancer stem cell. The breast cancer tissue is sarcoma. The marker is CD24low/-CD44high. A method for producing the mutipotential cancer stem cell line comprises: a step of isolating a breast cancer cell from a breast cancer tissue; a step of first-culturing isolated breast cancer cell in floating medium; a step of collecting floated cells; and a step of sub-culturing the cells several times to produce mutipotential cancer stem cell line.
Abstract translation: 提供了一种制造多潜能癌干细胞系的方法，以克服抗癌药物的耐药性并最大限度地提高治疗癌症的效率。 多能癌细胞系来自乳腺癌组织，表达乳腺癌干细胞的标志物。 乳腺癌组织是肉瘤。 标记是CD24low / -CD44high。 产生多能性癌干细胞系的方法包括：从乳腺癌组织中分离乳腺癌细胞的步骤; 在浮动培养基中首先培养分离的乳腺癌细胞的步骤; 收集浮游细胞的一个步骤; 以及将细胞分次数次培养以产生多能性癌干细胞系的步骤。
-
公开(公告)号：KR1020080018617A
公开(公告)日：2008-02-28
申请号：KR1020060081020
申请日：2006-08-25
Applicant: 재단법인서울대학교산학협력재단
Abstract: A multipotential cell line I derived from cancer tissue is provided to treat various diseases by differentiating into various types of cells including epidermal cell and nerve cell, study on the cancer development mechanism, and develop a new anticancer agent targeting proteins expressed from the same cell line. A multipotential cell line I(KCLRF-BP-00137) is derived from cancer tissue, can be cultured in a suspension state, and expresses markers of breast stem cell(CK19, CK5, CK6), a marker of breast cancer resistant drug(ABCG2), a marker of breast cancer diagnosis receptor(C-erBb2), markers of epidermal cell(CK14, vimentin, CK18) and markers of nerve cell(nestin, Tuj-1). A method for preparing the multipotential cell line I(KCLRF-BP-00137) comprises the steps of: (1) separating cancer cells from the previously separated cancer tissue; (2) culturing the separated cancer cells in a suspension medium; (3) collecting the cells in a suspension state from the cultured medium; and (4) subculturing the collected cells in a suspension medium to separate the multipotential cell line. Further, the cancer tissue is breast cancer.
Abstract translation: 提供衍生自癌组织的多能细胞系I，通过分化成包括表皮细胞和神经细胞在内的各种细胞，研究癌症发展机制，开发一种靶向相同细胞系表达的蛋白质的新型抗癌剂来治疗各种疾病 。 多能细胞系I（KCLRF-BP-00137）衍生自癌组织，可以以悬浮状态进行培养，并表达乳腺癌细胞（CK19，CK5，CK6），乳腺癌抗药物（ABCG2 ），乳腺癌诊断受体（C-erBb2）的标志物，表皮细胞（CK14，波形蛋白，CK18）的标记物和神经细胞标记物（巢蛋白，Tuj-1）。 制备多潜能细胞系I（KCLRF-BP-00137）的方法包括以下步骤：（1）从先前分离的癌组织分离癌细胞; （2）在悬浮介质中培养分离的癌细胞; （3）从培养基中收集处于悬浮状态的细胞; 和（4）将收集的细胞传代培养在悬浮介质中以分离多潜能细胞系。 此外，癌组织是乳腺癌。
-
公开(公告)号：KR1020090126882A
公开(公告)日：2009-12-09
申请号：KR1020080053224
申请日：2008-06-05
Applicant: 재단법인서울대학교산학협력재단
IPC: C12Q1/68
CPC classification number: G06F19/34 , C12Q1/6886
Abstract: PURPOSE: A method for predicting prognosis of breast cancer is provided to accurately classify patients having breast cancer into high risk group or low risk group. CONSTITUTION: A method for predicting prognosis of breast cancer comprises: a step of having information of Ki-67, bcl-2, or ER gene expression level from breast cancer cell; and a step of classifying patient into high risk group or low risk group using decision tree. In the decision tree, root node is Ki-67 gene, inner node is bcl-2 gene, ER gene and patient's age and terminal node is high risk group and low risk group.
Abstract translation: 目的：提供一种预测乳腺癌预后的方法，将乳腺癌患者准确分类为高危组或低危组。 构成：预测乳腺癌预后的方法包括：从乳腺癌细胞获得Ki-67，bcl-2或ER基因表达水平的信息的步骤; 以及使用决策树将患者分类为高风险组或低风险组的步骤。 在决策树中，根节点为Ki-67基因，内部节点为bcl-2基因，ER基因和患者年龄，终末节点为高风险组和低风险组。
-
公开(公告)号：KR1020060110542A
公开(公告)日：2006-10-25
申请号：KR1020050032872
申请日：2005-04-20
Applicant: 재단법인서울대학교산학협력재단
Abstract: Stem cells derived from the normal breast tissue and breast cancer tissue, a preparation method thereof and differentiated cells from the same stem cells are provided to be differentiated into various cells in human body, so that various diseases are treated. The multi-functional stem cells derived from the normal breast tissue and breast cancer tissue are provided, wherein the stem cells are capable of being differentiated into epidermal cells, nerve cells or bone marrow cells. The method for preparing the multi-functional stem cells derived from the breast tissue comprises the steps of: (a) separating breast cells from the breast tissue; (b) culturing the breast cells in a medium; (c) collecting the floating breast cells from the cultured medium; and (d) subculturing the floating breast cells in a medium and separating the multi-functional stem cells. The differentiated cells are prepared by (a) culturing the multi-functional stem cells derived from the breast tissue in a medium, and (b) separating the target differentiated cells expressing a marker during the cultivation, wherein the target differentiated cell is an epidermal cell, nerve cell or bone marrow cell.
Abstract translation: 提供衍生自正常乳腺组织和乳腺癌组织的干细胞，其制备方法和来自相同干细胞的分化细胞以分化成人体中的各种细胞，从而治疗各种疾病。 提供衍生自正常乳腺组织和乳腺癌组织的多功能干细胞，其中干细胞能够分化为表皮细胞，神经细胞或骨髓细胞。 从乳房组织制备多功能干细胞的方法包括以下步骤：（a）从乳房组织分离乳腺细胞; （b）在培养基中培养乳腺细胞; （c）从培养基中收集浮动的乳腺细胞; 和（d）将介质中的浮动乳腺细胞传代培养并分离多功能干细胞。 分化细胞通过（a）在培养基中培养衍生自乳腺组织的多功能干细胞，和（b）在培养期间分离表达标志物的靶分化细胞，其中靶分化细胞是表皮细胞 ，神经细胞或骨髓细胞。
-
公开(公告)号：KR1020100011766A
公开(公告)日：2010-02-03
申请号：KR1020080073115
申请日：2008-07-25
Applicant: 재단법인서울대학교산학협력재단
Abstract: PURPOSE: A target therapeutic agent of cancer stem cells using berberine is provided to suppress the expression of drug resistance target factor and induces apoptosis of cancer stem cells. CONSTITUTION: A target therapeutic agent of cancer stem cells contains berberine of chemical formula 1, its derivative or their pharmaceutically acceptable salt as an active ingredient. In chemical formula 1, X is halogen atom or sulfate. The cancer stem cell is breast cancer stem cells. The breast cancer cells express target factor of breast cancer stem cell, target factor of breast cancer resistance drug, target factor of breast cancer diagnostic receptor, target factor of epithelial cells, or target factor of neural cells. The breast cancer stem cell is deposit number KCLRF-BP-00137, KCLRF-BP-00138 or KCLRF-BP-00174. A food composition for preventing or treating cancer stem cells contains the berberine of chemical formula 1, its derivative or their salt as an active ingredient.
Abstract translation: 目的：提供使用小檗碱的癌干细胞靶向治疗剂，抑制药物抗性靶因子的表达，诱导癌细胞凋亡。 构成：癌干细胞的靶治疗剂含有化学式1的小檗碱，其衍生物或其药学上可接受的盐作为活性成分。 在化学式1中，X是卤素原子或硫酸根。 癌症干细胞是乳腺癌干细胞。 乳腺癌细胞表达乳腺癌干细胞的靶因子，乳腺癌抗药性的靶因子，乳腺癌诊断受体的靶因子，上皮细胞的靶因子或神经细胞的靶因子。 乳腺癌干细胞是保藏号KCLRF-BP-00137，KCLRF-BP-00138或KCLRF-BP-00174。 用于预防或治疗癌症干细胞的食物组合物含有化学式1的小檗碱，其衍生物或其盐作为活性成分。
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.02 seconds)
